MedTrace Logo

DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC)

NCT03474354 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-01-06

No results posted yet for this study

Summary

The primary purpose of the study is to evaluate the distribution of radiopaque microspheres loaded with doxorubicin in the treatment of unresectable HCC. Prospective, single arm, open label, single centre, pilot study. All patients will undergo clinical follow-up. Twenty patients will be enrolled.

Conditions

  • Hepatocellular Cancer
  • Chemoembolization

Interventions

DEVICE

chemoembolization

correlation of necrosis with the deposition of beads

Sponsors & Collaborators

  • Malagari Katerina

    lead OTHER

Principal Investigators

  • KATERINA MALAGARI · Evgenidion Hospital Athens, Greece

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-02
Primary Completion
2022-01-05
Completion
2022-01-05

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03474354 on ClinicalTrials.gov